# Thymosin Alpha-1 for irAE Secondary to ICIs

> **NCT06178146** · PHASE4 · UNKNOWN · sponsor: **Jun Wang** · enrollment: 40 (estimated)

## Conditions studied

- IrAE

## Interventions

- **DRUG:** Thymosin Alpha1
- **DRUG:** Immunosuppressant

## Key facts

- **NCT ID:** NCT06178146
- **Lead sponsor:** Jun Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-01
- **Primary completion:** 2024-11
- **Final completion:** 2025-04
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06178146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06178146, "Thymosin Alpha-1 for irAE Secondary to ICIs". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06178146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*